Skip to content
Screener

LB Pharmaceuticals Inc LBRX Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$152.27B+14.9%
Alkermes logo
AlkermesALKS
$9.79B+123%
MapLight Therapeutics, Inc. logo
MapLight Therapeutics, Inc.MPLT
$812.61M—
Alto Neuroscience logo
Alto NeuroscienceANRO
$474.75M+712%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$4.02B+13.2%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$5.72B+144%

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M—
Total debt$3.5M—
Total equity$378.7M+481%
Total assets$393.5M—

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$1.38B+309%

Returns & leverage

See full
Return on equity-27.9%—
Debt / equity0×—
Current ratio35.7×—

Where this comes from

Calculated from LB Pharmaceuticals Inc’s reported figures.

$707.1Mmarket cap+$3.5Mtotal debt−$320.7Mcash and equivalents=$389.92M

The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219607

FAQ

What is LB Pharmaceuticals Inc's enterprise value?
LB Pharmaceuticals Inc (LBRX) reported enterprise value of $389.92M in Q1 2026.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

Ask your AI about LB Pharmaceuticals Inc's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude